CARCINOMA, HEPATOCELLULAR
Clinical trials for CARCINOMA, HEPATOCELLULAR explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, HEPATOCELLULAR trials appear
Sign up with your email to follow new studies for CARCINOMA, HEPATOCELLULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for liver cancer patients with limited options after immunotherapy fails
Disease control Not yet recruitingThis study tests the drug regorafenib in about 20 adults with advanced liver cancer and moderate liver impairment (Child-Pugh B) whose cancer worsened after first-line immunotherapy. Participants take regorafenib pills daily for 3 weeks, then 1 week off, until the cancer progress…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Second-line hope for liver cancer: regorafenib tested after lenvatinib failure
Disease control Not yet recruitingThis study tests a drug called regorafenib in about 24 adults with advanced liver cancer that did not respond to the first treatment, lenvatinib. The goal is to see if regorafenib can slow tumor growth and improve survival. Participants will take regorafenib pills and have regula…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE2 • Sponsor: Ju Hyun Shim • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to stop liver cancer return in High-Risk patients
Disease control Not yet recruitingThis study tests a new two-drug approach for liver cancer patients whose tumors show 'tumor budding,' a sign of high recurrence risk. After surgery, participants receive a collagen-degrading drug plus a targeted therapy to help drugs reach cancer cells and kill them. The goal is …
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE4 • Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC